The clinical impact of pulmonary capillary wedge pressure (PCWP) on long-term mortality among patients with pulmonary arterial hypertension (PAH) has been incompletely reported, particularly in relation to concomitant treprostinil administration. The goal of this study was to assess the impact of PCWP on long-term mortality in PAH patients treated with parenteral treprostinil.
We studied a cohort of 743 patients with PAH treated with parenteral treprostinil therapy. The long-term all-cause mortality was compared in patients with baseline mean PCWP ≤ 8 mmHg, 8 < PCWP ≤ 11 mmHg, and PCWP > 11 mmHg over 4-year follow-up.
Of the 743 patients studied, 280 patients (37.7%) had a baseline mean PCWP ≤ 8 mmHg, 233 patients (31.4%) had a mean PCWP of >8 mmHg and ≤11 mmHg, and 230 patients (31.0%) had a mean PCWP >11 mmHg. While patients with higher PCWP had higher mean right atrial and PA pressures, no difference was noted in cardiac output and pulmonary vascular resistance (PVR). All-cause mortality was similar between patients with PCWP ≤8 mmHg, 8 < PCWP ≤ 11 mmHg, and PCWP > 11 mmHg at 1 year (10.4% vs 9.9% vs 10.0%, p = 0.980) and 4 years (16.8% vs 21.9% vs 19.2%, p = 0.353) respectively. In multivariate analysis, PCWP was not independently predictive of 4-year all-cause mortality [HR 1.00, 95%CI 0.95–1.05, p = 0.98 (per mmHg)]. Predictors of 4-year mortality included older age [HR 1.02, 95%CI 1.00–1.03, p = 0.0091 (per year)], non-Caucasian race, and higher PVR [HR 1.06, 95% CI 1.04–1.08, p < 0.0001 (per Woods Unit)].
In this study of patients with PAH receiving parenteral treprostinil, PCWP was not associated with long-term all-cause mortality. Further studies examining prognostic indicators in patients with PAH optimised on guideline-based therapies are warranted.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart, Lung and Circulation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.Chest. 2014; 146: 449-475
- Pulmonary arterial hypertension: epidemiology and registries.J Am Coll Cardiol. 2013; 62: D51-D59
- Diagnosis and assessment of pulmonary arterial hypertension.J Am Coll Cardiol. 2009; 54: S55-S66
- Survival in patients with primary pulmonary hypertension:. Results from a national prospective registry.Ann Intern Med. 1991; 115: 343-349
- An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.Chest. 2012; 142: 448-456
- Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mmHg: insights from the REVEAL registry.Chest. 2013; 143: 185-195
- A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).Am Heart J. 1997; 134: 44-54
- Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2010; 29 (TRUST): 137-149
- Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double blind, randomized, placebo-controlled trial.Am J Respir Crit Care Med. 2002; 165 (SC-TRE): 800-804
- Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.Eur Respir J. 2006; 28: 1195-1203
- Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.Chest. 2010; 137: 376-387
- Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.The European Respiratory Journal. 2006; 28: 1195-1203
- Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.Chest. 2013; 144: 160-168
- Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.The Journal of Heart and Lung Transplantation: the official publication of the International Society for Heart Transplantation. 2011; 30: 982-989
- Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.Journal of Cardiovascular Pharmacology and Therapeutics. 2015; 20: 395-400
- Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension.J Heart Lung Transplant. 2016; 35: 760-767
- Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension.Pulmonary Circulation. 2014; 4: 311-318
- Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.Chest. 2013; 144: 169-176
- Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension.Chest. 2015; 147: 198-208
- Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.Arthritis Care Res (Hoboken). 2014; 66: 489-495
- Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension.Chest. 2014; 146: 1478-1485
- Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.Chest. 2013; 143: 315-323
Published online: March 22, 2017
Accepted: February 12, 2017
Received in revised form: December 17, 2016
Received: May 5, 2016
© 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.